Tamtam Try Tamtam free
Haemonetics logo

Haemonetics account plan

Medical products development

At a glance

Haemonetics is a Boston-based medical technology company in plasma collection, apheresis and hospital devices, with $1,334.0 million fiscal 2026 revenue.

Haemonetics is a Boston-based medical technology company that sells plasma collection systems to biopharmaceutical plasma fractionators, apheresis products to blood centers, and hospital technologies (vascular closure, sensor-guided guidewires, hemostasis testing, cell salvage, transfusion software) in approximately 90 countries. Its model is largely razor/razor-blade: devices, mostly built by contract manufacturers, plus consumables it largely makes itself in North America and Malaysia. In fiscal 2026 (52 weeks to March 28, 2026) net revenues were $1,334.0 million (down 2.0%), operating income $156.7 million and net income $97.3 million, with 73.6% of revenue in the United States. It employed 3,009 full-time equivalent people at March 28, 2026, about 78% in North America. Since June 5, 2026 it reports two segments, Apheresis and MedSurg; Christopher A. Simon is President and Chief Executive Officer.

Business units

Strategic priorities

Grow Plasma through the CSL rollout and Persona PLUS
An August 14, 2026 non-exclusive supply agreement lets CSL Plasma use NexSys PCS with Persona PLUS; Haemonetics expects to complete the rollout to all CSL U.S. centers before the end of calendar 2027, adding approximately 50% more volume to Plasma. Persona PLUS delivers roughly an additional 5% yield per donation.
Shift the portfolio to higher-growth, higher-margin lines
Management sees Plasma and Hospital (now MedSurg) as the growth engines; Whole Blood was divested and Blood Center is focused on plasma and platelets. Gross margin rose to 59.0% in fiscal 2026 from 55.0%.
Launch new MedSurg products
Fiscal 2027 is called the year of launch: the VASCADE MVP XL expanded label (CE Mark and Japanese approval), the PacePro TAVR guidewire, and FDA approval of PerQseal Elite in October 2026 for a large-bore closure market sized at $300 million. These launches are not expected to contribute materially to fiscal 2027 revenue.
Expand operating margins over time
Management aims for high 20s operating margins or better as the business scales, with margin gains expected in fiscal 2028 after transitory production and freight costs.
Focus resources on the fastest-growing markets
A market and regional alignment initiative approved in May 2025 directs resources to the markets and geographies with the greatest growth; cumulative costs reached $7.9 million by the first half of fiscal 2027.
Capital allocation: organic first, then debt and buybacks
Organic investment comes first, then debt paydown; $325.0 million remains under the April 2025 buyback program and $100.0 million of revolver borrowings were repaid in the first half of fiscal 2027.

Latest results

In Q2 fiscal 2027 (quarter ended September 26, 2026) net revenues rose 9.3% to $357.8 million (10.0% organic), with Apheresis at $204.8 million (+12.6%) and MedSurg at $153.0 million (+5.1%). Plasma grew 16.5% on volume growth and share gains. Gross margin reached 61.7% (59.5% a year earlier), helped by tariff refunds, and operating income rose 28.4% to $75.1 million; diluted EPS was $1.00 (adjusted EPS $1.35). First-half revenue was $697.1 million (+7.5%) and first-half operating cash flow $180.4 million (vs $128.7 million). Fiscal 2027 guidance was raised to 8-11% reported and 6-9% organic revenue growth, while adjusted operating margin expansion was cut to 0-50 bps on personnel costs, performance pay and freight.

Investments and deals

Vivasure acquisition
Acquired Vivasure (Galway, PerQseal Elite large-bore closure) on January 9, 2026; the purchase price is now stated as $166.0 million. It extends vascular closure into large-bore TAVR, EVAR and mechanical circulatory support procedures.
New capex cycle for the CSL ramp
The CSL ramp will start a new capex cycle, with elevated capital expenditures over the next two years for manufacturing lines, packaging, warehousing and devices; production is rising by over 40%. First-half fiscal 2027 capex was $22.7 million.
Global ERP and digital transformation
A new global ERP system is being implemented, with $21.5 million of digital transformation costs in fiscal 2026.
Debt refinancing and buybacks
The $300.0 million 2026 convertible notes were repaid on March 2, 2026; $175.0 million of shares were repurchased in fiscal 2026. Net debt fell to $863.0 million at September 26, 2026 from $979.1 million at March 28, 2026.

Challenges and risks

Plasma customer concentration
The ten largest customers were about 44% of fiscal 2026 net revenues and one Plasma customer about 13%; the CSL agreement is non-exclusive with no minimum purchase commitments.
Esophageal cooling and goodwill headroom
Fiscal 2026 carried $86.5 million of intangible impairments, $77.2 million on Attune Medical after pulsed field ablation reduced the esophageal cooling opportunity. Interventional Technologies goodwill headroom is only 6%.
Cost inflation and tariffs
Adjusted operating expenses rose 15.2% in Q2 fiscal 2027 on personnel costs and freight; oil, transport and material inflation and tariffs weigh on costs, and supply chain risks include sole-source suppliers and single-site manufacturing.
Competition
Plasma and blood center products compete with Fresenius and Terumo BCT and Chinese entrants; patent suits against Terumo BCT and Fresenius Kabi continue. Hospital products face Terumo, Abbott, Cordis, Teleflex, Boston Scientific and Philips.
Declining blood center markets
Declining transfusion rates in mature markets and intensified competition in multi-unit collection have weighed on Blood Center growth; Other Apheresis revenue was flat in Q2 fiscal 2027.

What leadership says

“Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities.”

Christopher Simon, President and Chief Executive Officer · Q2 fiscal 2027 results press release, November 5, 2026

“we're still very confident that this is a business that can deliver high 20s operating margins or better as we scale.”

Christopher Simon, President and Chief Executive Officer · Q2 fiscal 2027 earnings call, November 5, 2026

“Essentially all of our contracts now are global in scope.”

Christopher Simon, President and Chief Executive Officer · Q1 fiscal 2027 earnings call, August 6, 2026

“We started FY27 strong with broad-based execution driving another quarter of profitable growth.”

Christopher Simon, President and Chief Executive Officer · Q1 fiscal 2027 earnings call, August 6, 2026

Where a supplier can help

Manufacturing and warehousing capacity for the CSL ramp
The new capex cycle for manufacturing lines, packaging, warehousing and devices opens room for equipment, automation and logistics suppliers supporting the CSL rollout.
Freight and cost control
With freight, oil and material inflation cutting margin expansion guidance, suppliers of logistics optimisation, procurement and supply chain resilience can tie their offer to the stated high 20s operating margin aim.
ERP and digital transformation support
The global ERP implementation and digital transformation costs point to needs for integration, data migration and IT and cybersecurity services.
Commercial launch support for MedSurg
The stepwise PerQseal Elite launch with heavy physician training, and the VASCADE MVP XL and PacePro launches, fit providers of clinical training, medical education and sales enablement.
Regional go-to-market focus
The market and regional alignment initiative and global plasma contracts suggest demand for market data, territory planning and international distribution support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Haemonetics?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Haemonetics

What does Haemonetics do?

Haemonetics is a Boston-based medical technology company. It sells plasma collection systems to plasma fractionators, apheresis products to blood centers, and hospital technologies such as vascular closure, hemostasis testing and transfusion software in approximately 90 countries.

What is Haemonetics' revenue?

Net revenues were $1,334.0 million in fiscal 2026 (52 weeks to March 28, 2026), down 2.0%. In Q2 fiscal 2027 revenue was $357.8 million, up 9.3%, and fiscal 2027 guidance calls for 8-11% reported growth.

How many employees does Haemonetics have?

Haemonetics employed the full-time equivalent of 3,009 people at March 28, 2026, about 78% in North America.

What is Haemonetics' strategy?

It is focusing on Plasma and MedSurg as growth engines, rolling out NexSys PCS with Persona PLUS across CSL's U.S. centers by the end of calendar 2027, launching new vascular closure and guidewire products, and aiming for high 20s operating margins as it scales.

Who leads Haemonetics?

Christopher A. Simon is President and Chief Executive Officer, and James C. D'Arecca is Executive Vice President and Chief Financial Officer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)